Myeloid leukemia after hematotoxins

Area of Science:

• Oncology
• Hematology
• Cancer Genetics

Background:

• Cancer therapy, while life-saving, carries the risk of secondary malignancies, particularly leukemia.
• Distinguishing between different types of therapy-related leukemia is crucial for understanding their distinct characteristics and outcomes.

Purpose of the Study:

• To differentiate and characterize distinct subsets of therapy-related leukemia.
• To elucidate the varying latency periods, clinical phenotypes, and genetic abnormalities associated with different therapy-induced leukemias.

Main Methods:

• Review and synthesis of existing literature on therapy-related leukemias.
• Analysis of clinical and genetic features of distinct leukemia subtypes.
• Comparison of therapy-related leukemias with de novo leukemia counterparts.

Main Results:

• Classic therapy-related myeloid leukemia (t-ML) presents with a longer latency (5-7 years), myelodysplastic phase, and chromosomal abnormalities (5q/7q).
• Topoisomerase II inhibitor-related leukemias exhibit shorter latency, monoblastic/myelomonocytic phenotypes, and specific translocations (11q23, 21q22) involving MLL or AML1 genes.
• Therapy-related acute lymphoblastic leukemia (t-ALL) also shows 11q23 rearrangements.
• Leukemias with 11q23/21q22 rearrangements, inv(16), or t(15;17) demonstrate a more favorable prognosis.

Conclusions:

• Therapy-related leukemias are heterogeneous, with distinct subtypes arising from different treatments and characterized by specific genetic alterations.
• Understanding these subtypes is essential for predicting prognosis and guiding treatment decisions, including bone marrow transplantation for poor-prognosis cases.
• Certain genetic rearrangements in therapy-related leukemias correlate with a better response to treatment, similar to de novo cases.